Wilding JP - Search Results

1

Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus inadequately controlled with metformin and sulphonylurea: a randomised trial.

Wilding JP, Charpentier G, Hollander P, González-Gálvez G, Mathieu C, Vercruysse F, Usiskin K, Law G, Black S, Canovatchel W, Meininger G. Wilding JP, et al. Int J Clin Pract. 2013 Dec;67(12):1267-82. doi: 10.1111/ijcp.12322. Epub 2013 Oct 13. Int J Clin Pract. 2013. PMID: 24118688 Free PMC article. Clinical Trial.

2

Obesity and diabetes.

Leong KS, Wilding JP. Leong KS, et al. Among authors: wilding jp. Baillieres Best Pract Res Clin Endocrinol Metab. 1999 Jul;13(2):221-37. doi: 10.1053/beem.1999.0017. Baillieres Best Pract Res Clin Endocrinol Metab. 1999. PMID: 10761864 Review.

3

Obesity and Type 2 diabetes mellitus.

Wilding J. Wilding J. Diabet Med. 2000 May;17(5):400-2. doi: 10.1046/j.1464-5491.2000.00292-5.x. Diabet Med. 2000. PMID: 10872543 No abstract available.

4

Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study.

Broom I, Wilding J, Stott P, Myers N; UK Multimorbidity Study Group. Broom I, et al. Int J Clin Pract. 2002 Sep;56(7):494-9. Int J Clin Pract. 2002. PMID: 12296610 Clinical Trial.

5

Intensified treatment of type 2 diabetes--positive effects on blood pressure, but not glycaemic control.

Gill GV, Woodward A, Pradhan S, Wallymahmed M, Groves T, English P, Wilding JP. Gill GV, et al. Among authors: wilding jp. QJM. 2003 Nov;96(11):833-6. doi: 10.1093/qjmed/hcg143. QJM. 2003. PMID: 14566038

6

A randomized double-blind placebo-controlled study of the long-term efficacy and safety of topiramate in the treatment of obese subjects.

Wilding J, Van Gaal L, Rissanen A, Vercruysse F, Fitchet M; OBES-002 Study Group. Wilding J, et al. Int J Obes Relat Metab Disord. 2004 Nov;28(11):1399-410. doi: 10.1038/sj.ijo.0802783. Int J Obes Relat Metab Disord. 2004. PMID: 15486569 Clinical Trial.

7

Metformin prolongs the postprandial fall in plasma ghrelin concentrations in type 2 diabetes.

English PJ, Ashcroft A, Patterson M, Dovey TM, Halford JC, Harrison J, Eccleston D, Bloom SR, Ghatei MA, Wilding JP. English PJ, et al. Among authors: wilding jp. Diabetes Metab Res Rev. 2007 May;23(4):299-303. doi: 10.1002/dmrr.681. Diabetes Metab Res Rev. 2007. PMID: 16952199

8

Thiazolidinediones, insulin resistance and obesity: Finding a balance.

Wilding J. Wilding J. Int J Clin Pract. 2006 Oct;60(10):1272-80. doi: 10.1111/j.1742-1241.2006.01128.x. Int J Clin Pract. 2006. PMID: 16981971 Review.

9

Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes.

Wilding JP, Gause-Nilsson I, Persson A; GALLANT 7 Study Group. Wilding JP, et al. Diab Vasc Dis Res. 2007 Sep;4(3):194-203. doi: 10.3132/dvdr.2007.040. Diab Vasc Dis Res. 2007. PMID: 17907109 Free article. Clinical Trial.

10

A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment.

Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. Wilding JP, et al. Diabetes Care. 2009 Sep;32(9):1656-62. doi: 10.2337/dc09-0517. Epub 2009 Jun 15. Diabetes Care. 2009. PMID: 19528367 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

327 results

Search Page